Sellas Life Sciences Group Inc (SLS) - Total Liabilities
Based on the latest financial reports, Sellas Life Sciences Group Inc (SLS) has total liabilities worth $7.47 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SLS cash generation efficiency to assess how effectively this company generates cash.
Sellas Life Sciences Group Inc - Total Liabilities Trend (2007–2025)
This chart illustrates how Sellas Life Sciences Group Inc's total liabilities have evolved over time, based on quarterly financial data. Check SLS asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Sellas Life Sciences Group Inc Competitors by Total Liabilities
The table below lists competitors of Sellas Life Sciences Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RIAMB (Beijing) Tech Dvlp Co
SHG:603082
|
China | CN¥2.69 Billion |
|
Lg Electronics Pref
KO:066575
|
Korea | ₩40.25 Trillion |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
China | CN¥26.09 Billion |
|
Omnijoi Media Corp
SHE:300528
|
China | CN¥1.46 Billion |
|
Kayne Anderson BDC, Inc.
NYSE:KBDC
|
USA | $1.18 Billion |
|
Kumho Tire
KO:073240
|
Korea | ₩3.30 Trillion |
|
Gentherm Inc
NASDAQ:THRM
|
USA | $713.82 Million |
|
Bata India Limited
NSE:BATAINDIA
|
India | Rs21.67 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Sellas Life Sciences Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sellas Life Sciences Group Inc (SLS) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sellas Life Sciences Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sellas Life Sciences Group Inc (2007–2025)
The table below shows the annual total liabilities of Sellas Life Sciences Group Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.47 Million | -25.01% |
| 2024-12-31 | $9.97 Million | -29.79% |
| 2023-12-31 | $14.20 Million | -11.79% |
| 2022-12-31 | $16.09 Million | +164.67% |
| 2021-12-31 | $6.08 Million | -66.39% |
| 2020-12-31 | $18.09 Million | +72.00% |
| 2019-12-31 | $10.52 Million | -9.89% |
| 2018-12-31 | $11.67 Million | -62.90% |
| 2017-12-31 | $31.46 Million | -15.34% |
| 2016-12-31 | $37.15 Million | -45.86% |
| 2015-12-31 | $68.63 Million | +58.03% |
| 2014-12-31 | $43.43 Million | -47.10% |
| 2013-12-31 | $82.09 Million | +201.47% |
| 2012-12-31 | $27.23 Million | +30.56% |
| 2011-12-31 | $20.86 Million | +313.32% |
| 2010-12-31 | $5.05 Million | -8.44% |
| 2009-12-31 | $5.51 Million | +296.19% |
| 2008-12-31 | $1.39 Million | +5.06% |
| 2007-12-31 | $1.32 Million | -- |
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more